These findings suggest that the antiproliferative activity of BIQO-19 is associated with effective inhibition of aurora kinase A, which in turn leads to the induction of G2/M phase cell cycle arrest and apoptotic cell death in EGFR-TKI-resistant NSCLC cells. The gene discussed is AURKA; the disease is non-small cell lung carcinoma.